The approval relies on positive data from the POTOMAC Phase III trial.

With a recent FDA nod for Baxfendy under its belt, AstraZeneca is looking to grow its prowess in cardio disease, weight ...

This year's American Society of Clinical Oncology (ASCO) conference has been a subdued affair for European pharmaceutical ...

The data on the kappa AL amyloidosis group treated with anselamimab was presented by AstraZeneca at ASCO 2026.

AbbVie’s ADC has secured FDA clearance for an ultra-rare blood cancer while the agency has delayed its decision on ...

Drugmaker had stalled large-scale projects in England but has now pledged investment at two sites, announced by Keir Starmer ...

AstraZeneca announces CARES phase III clinical programme fails to meet primary endpoint in overall light chain amyloidosis population: Cambridge, UK Monday, June 1, 2026, 12:00 Hr ...

The advisory panel wasn't convinced that a clinical trial proved that early switching to camizestrant improved long-term ...

The FDA has delayed a decision on the approval of AstraZeneca’s camizestrant, deferring its ruling to review analyses filed ...

By Bhanvi Satija LONDON, May 18 (Reuters) - Anglo-Swedish drugmaker AstraZeneca said on Monday its hypertension pill ...